Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biochem Pharma (BCHE) -- Ignore unavailable to you. Want to Upgrade?

To: JDN who wrote (641)	7/16/1999 12:29:00 PM
From: Jim Oravetz	Respond to of 783

From this old reply, the two things holding BCHE down are: Message 9245941 "The fact that lamivudine sales were so low (US$800,000 vs est. for as high as $10M) rekindled uncertainty about the potential of the drug, said Michael Jams, an analyst with Levesque Beaubien Geoffrion Inc...." "Earlier in the year, several analysts wrote reports warning about what a proposed change in U.S. accounting rules could do to BioChem's income statement...." IMHO, until these issues are resolved, especially the much anticipated uptick in lamivudine sales, the stock will track in a narrow range. Jim